The effect of Imatinib Mesylate in diffuse-type Tenosynovial Giant Cell Tumours on MR imaging and PET-CT
Recurrence rates remain high after surgical treatment of diffuse-type Tenosynovial Giant Cell Tumour (TGCT). Imatinib Mesylate (IM) blocks Colony Stimulating Factor1 Receptor (CSF1R), the driver mechanism in TGCT. The aim of this study was to determine if IM reduces the tumour metabolic activity eva...
Gespeichert in:
Veröffentlicht in: | Surgical oncology 2020-12, Vol.35, p.261-267 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 267 |
---|---|
container_issue | |
container_start_page | 261 |
container_title | Surgical oncology |
container_volume | 35 |
creator | Mastboom, M.J.L. Lips, W. van Langevelde, K. Mifsud, M. Ng, C. McCarthy, C.L. Athanasou, N.A. Gibbons, C.L.M.H. van de Sande, M.A.J. |
description | Recurrence rates remain high after surgical treatment of diffuse-type Tenosynovial Giant Cell Tumour (TGCT). Imatinib Mesylate (IM) blocks Colony Stimulating Factor1 Receptor (CSF1R), the driver mechanism in TGCT. The aim of this study was to determine if IM reduces the tumour metabolic activity evaluated by PET-CT and to compare this response with the response seen on MR imaging.
25 Consecutive patients treated with IM (off label use) for locally advanced (N = 12) or recurrent (N = 13) diffuse-type TGCT were included, 15 male and median age at diagnosis 39 (IQR 31–47) years. The knee was most frequently affected (n = 16; 64%). The effect of IM was assessed pre- and post-IM treatment by comparing MR scans and PET-CT. MR scans were assessed by Tumour Volume Score (TVS), an estimation of the tumour volume as a percentage of the total synovial cavity. PET-CT scans were evaluated based on maximum standardized uptake value (SUV-max). Partial response was defined as more than 50% tumour reduction with TVS and a decrease of at least 30% on SUV-max.
Median duration of IM treatment was 7.0 (IQR 4.2–11.5) months. Twenty patients (80%) discontinued IM treatment for poor response or intended surgery. Twenty patients experienced an adverse event grade 1–2, three patients grade 3 (creatinine increment, neutropenic sepsis, liver dysfunction). MR assessment of all joints showed 32% (6/19) partial response and 63% (12/19) stable disease, with a mean difference of 12% (P = 0.467; CI -22.4-46.0) TVS between pre- and post-IM and a significant mean difference of 23% (P = 0.021; CI 4.2–21.6) in all knee lesions. PET-CT, all joints, showed a significantly decreased mean difference of 5.3 (P = 0.004; CI 1.9–8.7) SUV-max between pre- and post-IM treatment (58% (11/19) partial response, 37% (7/19) stable disease). No correlation between MR imaging and PET-CT could be appreciated in 15 patients with complete radiological data.
This study confirms the moderate radiological response of IM in diffuse-type TGCT. PET-CT is a valuable additional diagnostic tool to quantify response to tyrosine kinase inhibitor treatment. Its value should be assessed further to validate its efficacy in the objective measurement of biological response in targeted systemic treatment of TGCT.
•Tenosynovial Giant Cell Tumour (TGCT), is a rare mono-articular tumour affecting the synovium, bursae and tendon sheath.•Diagnosing and staging the extension of TGCT is assessed on MR imaging and can be quantified by th |
doi_str_mv | 10.1016/j.suronc.2020.08.030 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2443521791</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0960740420303807</els_id><sourcerecordid>2468244048</sourcerecordid><originalsourceid>FETCH-LOGICAL-c436t-93898dda37d9e3d0a65169d3fa84f9cfce78e93eada039c899e78a1ec254ba4c3</originalsourceid><addsrcrecordid>eNp9kc1rFDEUwIModq3-ByIBL15mfPnYmeQiyFLbQosi4zlkk5c2y2yyTmYK-9-bsrUHD54ePH7v80fIewYtA9Z93rVlmXJyLQcOLagWBLwgK6Z63QjB4SVZge6g6SXIM_KmlB0AdD1nr8mZ4FpwzuWK3A_3SDEEdDPNgV7v7RxT3NJbLMfRzkhjoj6GsBRs5uMB6YApl2PKD9GO9DLaNNMNjiMdln1epkJzorc_adzbu5juqE2e_rgYms3wlrwKdiz47imek1_fLobNVXPz_fJ68_WmcVJ0c6OF0sp7K3qvUXiw3Zp12otglQzaBYe9Qi3QegtCO6V1TViGjq_l1konzsmnU9_DlH8vWGazj8XVDW3CvBTDpRRrznrNKvrxH3RXT0h1u0p1qpIgVaXkiXJTLmXCYA5TPW86Ggbm0YTZmZMJ82jCgDLVRC378NR82e7RPxf9fX0FvpwArN94iDiZ4iImhz5O1YbxOf5_wh8aNJsv</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2468244048</pqid></control><display><type>article</type><title>The effect of Imatinib Mesylate in diffuse-type Tenosynovial Giant Cell Tumours on MR imaging and PET-CT</title><source>Elsevier ScienceDirect Journals Complete</source><creator>Mastboom, M.J.L. ; Lips, W. ; van Langevelde, K. ; Mifsud, M. ; Ng, C. ; McCarthy, C.L. ; Athanasou, N.A. ; Gibbons, C.L.M.H. ; van de Sande, M.A.J.</creator><creatorcontrib>Mastboom, M.J.L. ; Lips, W. ; van Langevelde, K. ; Mifsud, M. ; Ng, C. ; McCarthy, C.L. ; Athanasou, N.A. ; Gibbons, C.L.M.H. ; van de Sande, M.A.J.</creatorcontrib><description>Recurrence rates remain high after surgical treatment of diffuse-type Tenosynovial Giant Cell Tumour (TGCT). Imatinib Mesylate (IM) blocks Colony Stimulating Factor1 Receptor (CSF1R), the driver mechanism in TGCT. The aim of this study was to determine if IM reduces the tumour metabolic activity evaluated by PET-CT and to compare this response with the response seen on MR imaging.
25 Consecutive patients treated with IM (off label use) for locally advanced (N = 12) or recurrent (N = 13) diffuse-type TGCT were included, 15 male and median age at diagnosis 39 (IQR 31–47) years. The knee was most frequently affected (n = 16; 64%). The effect of IM was assessed pre- and post-IM treatment by comparing MR scans and PET-CT. MR scans were assessed by Tumour Volume Score (TVS), an estimation of the tumour volume as a percentage of the total synovial cavity. PET-CT scans were evaluated based on maximum standardized uptake value (SUV-max). Partial response was defined as more than 50% tumour reduction with TVS and a decrease of at least 30% on SUV-max.
Median duration of IM treatment was 7.0 (IQR 4.2–11.5) months. Twenty patients (80%) discontinued IM treatment for poor response or intended surgery. Twenty patients experienced an adverse event grade 1–2, three patients grade 3 (creatinine increment, neutropenic sepsis, liver dysfunction). MR assessment of all joints showed 32% (6/19) partial response and 63% (12/19) stable disease, with a mean difference of 12% (P = 0.467; CI -22.4-46.0) TVS between pre- and post-IM and a significant mean difference of 23% (P = 0.021; CI 4.2–21.6) in all knee lesions. PET-CT, all joints, showed a significantly decreased mean difference of 5.3 (P = 0.004; CI 1.9–8.7) SUV-max between pre- and post-IM treatment (58% (11/19) partial response, 37% (7/19) stable disease). No correlation between MR imaging and PET-CT could be appreciated in 15 patients with complete radiological data.
This study confirms the moderate radiological response of IM in diffuse-type TGCT. PET-CT is a valuable additional diagnostic tool to quantify response to tyrosine kinase inhibitor treatment. Its value should be assessed further to validate its efficacy in the objective measurement of biological response in targeted systemic treatment of TGCT.
•Tenosynovial Giant Cell Tumour (TGCT), is a rare mono-articular tumour affecting the synovium, bursae and tendon sheath.•Diagnosing and staging the extension of TGCT is assessed on MR imaging and can be quantified by the Tumour Volume Score (TVS).•PET-CT provides understanding of the metabolic activity of TGCT, expressed as maximum Standardized Uptake Values (SUV-max).•As treatment in diffuse-type TGCT, Imatinib Mesylate, a tyrosine kinase inhibitor, can be provided.•PET-CT is a valuable additional diagnostic tool to quantify response to tyrosine kinase inhibitor treatment in TGCT.</description><identifier>ISSN: 0960-7404</identifier><identifier>EISSN: 1879-3320</identifier><identifier>DOI: 10.1016/j.suronc.2020.08.030</identifier><identifier>PMID: 32932224</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Computed tomography ; Creatinine ; Cysts ; Diagnostic software ; Diagnostic systems ; Enzyme inhibitors ; Evaluation ; Imatinib ; Imatinib mesylate ; Joints (anatomy) ; Kinases ; Knee ; Liver diseases ; Magnetic resonance imaging ; Medical imaging ; Metabolism ; Neutropenia ; Patients ; Positron emission ; Protein-tyrosine kinase ; Quality of life ; Radiation therapy ; Radiological response ; Sepsis ; Surgery ; Targeted cancer therapy ; Tenosynovial giant cell tumour ; Tomography ; Tumors ; Tyrosine</subject><ispartof>Surgical oncology, 2020-12, Vol.35, p.261-267</ispartof><rights>2021 The Authors</rights><rights>Copyright © 2020 Elsevier Ltd. All rights reserved.</rights><rights>2020. Elsevier Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c436t-93898dda37d9e3d0a65169d3fa84f9cfce78e93eada039c899e78a1ec254ba4c3</citedby><cites>FETCH-LOGICAL-c436t-93898dda37d9e3d0a65169d3fa84f9cfce78e93eada039c899e78a1ec254ba4c3</cites><orcidid>0000-0002-2844-6253 ; 0000-0002-8871-9081</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.suronc.2020.08.030$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32932224$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mastboom, M.J.L.</creatorcontrib><creatorcontrib>Lips, W.</creatorcontrib><creatorcontrib>van Langevelde, K.</creatorcontrib><creatorcontrib>Mifsud, M.</creatorcontrib><creatorcontrib>Ng, C.</creatorcontrib><creatorcontrib>McCarthy, C.L.</creatorcontrib><creatorcontrib>Athanasou, N.A.</creatorcontrib><creatorcontrib>Gibbons, C.L.M.H.</creatorcontrib><creatorcontrib>van de Sande, M.A.J.</creatorcontrib><title>The effect of Imatinib Mesylate in diffuse-type Tenosynovial Giant Cell Tumours on MR imaging and PET-CT</title><title>Surgical oncology</title><addtitle>Surg Oncol</addtitle><description>Recurrence rates remain high after surgical treatment of diffuse-type Tenosynovial Giant Cell Tumour (TGCT). Imatinib Mesylate (IM) blocks Colony Stimulating Factor1 Receptor (CSF1R), the driver mechanism in TGCT. The aim of this study was to determine if IM reduces the tumour metabolic activity evaluated by PET-CT and to compare this response with the response seen on MR imaging.
25 Consecutive patients treated with IM (off label use) for locally advanced (N = 12) or recurrent (N = 13) diffuse-type TGCT were included, 15 male and median age at diagnosis 39 (IQR 31–47) years. The knee was most frequently affected (n = 16; 64%). The effect of IM was assessed pre- and post-IM treatment by comparing MR scans and PET-CT. MR scans were assessed by Tumour Volume Score (TVS), an estimation of the tumour volume as a percentage of the total synovial cavity. PET-CT scans were evaluated based on maximum standardized uptake value (SUV-max). Partial response was defined as more than 50% tumour reduction with TVS and a decrease of at least 30% on SUV-max.
Median duration of IM treatment was 7.0 (IQR 4.2–11.5) months. Twenty patients (80%) discontinued IM treatment for poor response or intended surgery. Twenty patients experienced an adverse event grade 1–2, three patients grade 3 (creatinine increment, neutropenic sepsis, liver dysfunction). MR assessment of all joints showed 32% (6/19) partial response and 63% (12/19) stable disease, with a mean difference of 12% (P = 0.467; CI -22.4-46.0) TVS between pre- and post-IM and a significant mean difference of 23% (P = 0.021; CI 4.2–21.6) in all knee lesions. PET-CT, all joints, showed a significantly decreased mean difference of 5.3 (P = 0.004; CI 1.9–8.7) SUV-max between pre- and post-IM treatment (58% (11/19) partial response, 37% (7/19) stable disease). No correlation between MR imaging and PET-CT could be appreciated in 15 patients with complete radiological data.
This study confirms the moderate radiological response of IM in diffuse-type TGCT. PET-CT is a valuable additional diagnostic tool to quantify response to tyrosine kinase inhibitor treatment. Its value should be assessed further to validate its efficacy in the objective measurement of biological response in targeted systemic treatment of TGCT.
•Tenosynovial Giant Cell Tumour (TGCT), is a rare mono-articular tumour affecting the synovium, bursae and tendon sheath.•Diagnosing and staging the extension of TGCT is assessed on MR imaging and can be quantified by the Tumour Volume Score (TVS).•PET-CT provides understanding of the metabolic activity of TGCT, expressed as maximum Standardized Uptake Values (SUV-max).•As treatment in diffuse-type TGCT, Imatinib Mesylate, a tyrosine kinase inhibitor, can be provided.•PET-CT is a valuable additional diagnostic tool to quantify response to tyrosine kinase inhibitor treatment in TGCT.</description><subject>Computed tomography</subject><subject>Creatinine</subject><subject>Cysts</subject><subject>Diagnostic software</subject><subject>Diagnostic systems</subject><subject>Enzyme inhibitors</subject><subject>Evaluation</subject><subject>Imatinib</subject><subject>Imatinib mesylate</subject><subject>Joints (anatomy)</subject><subject>Kinases</subject><subject>Knee</subject><subject>Liver diseases</subject><subject>Magnetic resonance imaging</subject><subject>Medical imaging</subject><subject>Metabolism</subject><subject>Neutropenia</subject><subject>Patients</subject><subject>Positron emission</subject><subject>Protein-tyrosine kinase</subject><subject>Quality of life</subject><subject>Radiation therapy</subject><subject>Radiological response</subject><subject>Sepsis</subject><subject>Surgery</subject><subject>Targeted cancer therapy</subject><subject>Tenosynovial giant cell tumour</subject><subject>Tomography</subject><subject>Tumors</subject><subject>Tyrosine</subject><issn>0960-7404</issn><issn>1879-3320</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9kc1rFDEUwIModq3-ByIBL15mfPnYmeQiyFLbQosi4zlkk5c2y2yyTmYK-9-bsrUHD54ePH7v80fIewYtA9Z93rVlmXJyLQcOLagWBLwgK6Z63QjB4SVZge6g6SXIM_KmlB0AdD1nr8mZ4FpwzuWK3A_3SDEEdDPNgV7v7RxT3NJbLMfRzkhjoj6GsBRs5uMB6YApl2PKD9GO9DLaNNMNjiMdln1epkJzorc_adzbu5juqE2e_rgYms3wlrwKdiz47imek1_fLobNVXPz_fJ68_WmcVJ0c6OF0sp7K3qvUXiw3Zp12otglQzaBYe9Qi3QegtCO6V1TViGjq_l1konzsmnU9_DlH8vWGazj8XVDW3CvBTDpRRrznrNKvrxH3RXT0h1u0p1qpIgVaXkiXJTLmXCYA5TPW86Ggbm0YTZmZMJ82jCgDLVRC378NR82e7RPxf9fX0FvpwArN94iDiZ4iImhz5O1YbxOf5_wh8aNJsv</recordid><startdate>202012</startdate><enddate>202012</enddate><creator>Mastboom, M.J.L.</creator><creator>Lips, W.</creator><creator>van Langevelde, K.</creator><creator>Mifsud, M.</creator><creator>Ng, C.</creator><creator>McCarthy, C.L.</creator><creator>Athanasou, N.A.</creator><creator>Gibbons, C.L.M.H.</creator><creator>van de Sande, M.A.J.</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>P64</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-2844-6253</orcidid><orcidid>https://orcid.org/0000-0002-8871-9081</orcidid></search><sort><creationdate>202012</creationdate><title>The effect of Imatinib Mesylate in diffuse-type Tenosynovial Giant Cell Tumours on MR imaging and PET-CT</title><author>Mastboom, M.J.L. ; Lips, W. ; van Langevelde, K. ; Mifsud, M. ; Ng, C. ; McCarthy, C.L. ; Athanasou, N.A. ; Gibbons, C.L.M.H. ; van de Sande, M.A.J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c436t-93898dda37d9e3d0a65169d3fa84f9cfce78e93eada039c899e78a1ec254ba4c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Computed tomography</topic><topic>Creatinine</topic><topic>Cysts</topic><topic>Diagnostic software</topic><topic>Diagnostic systems</topic><topic>Enzyme inhibitors</topic><topic>Evaluation</topic><topic>Imatinib</topic><topic>Imatinib mesylate</topic><topic>Joints (anatomy)</topic><topic>Kinases</topic><topic>Knee</topic><topic>Liver diseases</topic><topic>Magnetic resonance imaging</topic><topic>Medical imaging</topic><topic>Metabolism</topic><topic>Neutropenia</topic><topic>Patients</topic><topic>Positron emission</topic><topic>Protein-tyrosine kinase</topic><topic>Quality of life</topic><topic>Radiation therapy</topic><topic>Radiological response</topic><topic>Sepsis</topic><topic>Surgery</topic><topic>Targeted cancer therapy</topic><topic>Tenosynovial giant cell tumour</topic><topic>Tomography</topic><topic>Tumors</topic><topic>Tyrosine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mastboom, M.J.L.</creatorcontrib><creatorcontrib>Lips, W.</creatorcontrib><creatorcontrib>van Langevelde, K.</creatorcontrib><creatorcontrib>Mifsud, M.</creatorcontrib><creatorcontrib>Ng, C.</creatorcontrib><creatorcontrib>McCarthy, C.L.</creatorcontrib><creatorcontrib>Athanasou, N.A.</creatorcontrib><creatorcontrib>Gibbons, C.L.M.H.</creatorcontrib><creatorcontrib>van de Sande, M.A.J.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Surgical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mastboom, M.J.L.</au><au>Lips, W.</au><au>van Langevelde, K.</au><au>Mifsud, M.</au><au>Ng, C.</au><au>McCarthy, C.L.</au><au>Athanasou, N.A.</au><au>Gibbons, C.L.M.H.</au><au>van de Sande, M.A.J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The effect of Imatinib Mesylate in diffuse-type Tenosynovial Giant Cell Tumours on MR imaging and PET-CT</atitle><jtitle>Surgical oncology</jtitle><addtitle>Surg Oncol</addtitle><date>2020-12</date><risdate>2020</risdate><volume>35</volume><spage>261</spage><epage>267</epage><pages>261-267</pages><issn>0960-7404</issn><eissn>1879-3320</eissn><abstract>Recurrence rates remain high after surgical treatment of diffuse-type Tenosynovial Giant Cell Tumour (TGCT). Imatinib Mesylate (IM) blocks Colony Stimulating Factor1 Receptor (CSF1R), the driver mechanism in TGCT. The aim of this study was to determine if IM reduces the tumour metabolic activity evaluated by PET-CT and to compare this response with the response seen on MR imaging.
25 Consecutive patients treated with IM (off label use) for locally advanced (N = 12) or recurrent (N = 13) diffuse-type TGCT were included, 15 male and median age at diagnosis 39 (IQR 31–47) years. The knee was most frequently affected (n = 16; 64%). The effect of IM was assessed pre- and post-IM treatment by comparing MR scans and PET-CT. MR scans were assessed by Tumour Volume Score (TVS), an estimation of the tumour volume as a percentage of the total synovial cavity. PET-CT scans were evaluated based on maximum standardized uptake value (SUV-max). Partial response was defined as more than 50% tumour reduction with TVS and a decrease of at least 30% on SUV-max.
Median duration of IM treatment was 7.0 (IQR 4.2–11.5) months. Twenty patients (80%) discontinued IM treatment for poor response or intended surgery. Twenty patients experienced an adverse event grade 1–2, three patients grade 3 (creatinine increment, neutropenic sepsis, liver dysfunction). MR assessment of all joints showed 32% (6/19) partial response and 63% (12/19) stable disease, with a mean difference of 12% (P = 0.467; CI -22.4-46.0) TVS between pre- and post-IM and a significant mean difference of 23% (P = 0.021; CI 4.2–21.6) in all knee lesions. PET-CT, all joints, showed a significantly decreased mean difference of 5.3 (P = 0.004; CI 1.9–8.7) SUV-max between pre- and post-IM treatment (58% (11/19) partial response, 37% (7/19) stable disease). No correlation between MR imaging and PET-CT could be appreciated in 15 patients with complete radiological data.
This study confirms the moderate radiological response of IM in diffuse-type TGCT. PET-CT is a valuable additional diagnostic tool to quantify response to tyrosine kinase inhibitor treatment. Its value should be assessed further to validate its efficacy in the objective measurement of biological response in targeted systemic treatment of TGCT.
•Tenosynovial Giant Cell Tumour (TGCT), is a rare mono-articular tumour affecting the synovium, bursae and tendon sheath.•Diagnosing and staging the extension of TGCT is assessed on MR imaging and can be quantified by the Tumour Volume Score (TVS).•PET-CT provides understanding of the metabolic activity of TGCT, expressed as maximum Standardized Uptake Values (SUV-max).•As treatment in diffuse-type TGCT, Imatinib Mesylate, a tyrosine kinase inhibitor, can be provided.•PET-CT is a valuable additional diagnostic tool to quantify response to tyrosine kinase inhibitor treatment in TGCT.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>32932224</pmid><doi>10.1016/j.suronc.2020.08.030</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-2844-6253</orcidid><orcidid>https://orcid.org/0000-0002-8871-9081</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0960-7404 |
ispartof | Surgical oncology, 2020-12, Vol.35, p.261-267 |
issn | 0960-7404 1879-3320 |
language | eng |
recordid | cdi_proquest_miscellaneous_2443521791 |
source | Elsevier ScienceDirect Journals Complete |
subjects | Computed tomography Creatinine Cysts Diagnostic software Diagnostic systems Enzyme inhibitors Evaluation Imatinib Imatinib mesylate Joints (anatomy) Kinases Knee Liver diseases Magnetic resonance imaging Medical imaging Metabolism Neutropenia Patients Positron emission Protein-tyrosine kinase Quality of life Radiation therapy Radiological response Sepsis Surgery Targeted cancer therapy Tenosynovial giant cell tumour Tomography Tumors Tyrosine |
title | The effect of Imatinib Mesylate in diffuse-type Tenosynovial Giant Cell Tumours on MR imaging and PET-CT |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T09%3A06%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20effect%20of%20Imatinib%20Mesylate%20in%20diffuse-type%20Tenosynovial%20Giant%20Cell%20Tumours%20on%20MR%20imaging%20and%20PET-CT&rft.jtitle=Surgical%20oncology&rft.au=Mastboom,%20M.J.L.&rft.date=2020-12&rft.volume=35&rft.spage=261&rft.epage=267&rft.pages=261-267&rft.issn=0960-7404&rft.eissn=1879-3320&rft_id=info:doi/10.1016/j.suronc.2020.08.030&rft_dat=%3Cproquest_cross%3E2468244048%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2468244048&rft_id=info:pmid/32932224&rft_els_id=S0960740420303807&rfr_iscdi=true |